BINAY CHAUBEY

Dr. BINAY CHAUBEY


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


1 December 2022 in AIDS Research and Therapy
Verified
Journal Article
Open access
PDF file
RBRuchira Bhowmik
Ruchira Bhowmik
BCBINAY CHAUBEY
BINAY CHAUBEY
The development of antiretroviral therapy (ART) has been effective in suppressing HIV replication. However, severe drug toxicities due to the therapy and its failure in targeting the integrated proviral genome have led to the introduction of a new paradigm of gene-based therapies. With its effective inhibition and high precision, clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein-9 nuclease (Cas9) or CRISPR/Cas9 has emerged as an effective genome editing tool in the last decade. Mediated by guide RNAs (gRNAs), Cas9 endonuclease acts like genetic scissors that can modify specific target sites. With this concept, CRISPR/Cas9 has been used to target the integrated proviral HIV-1 genome both in in vitro as well as in vivo studies including non-human primates. The CRISPR has also been tested for targeting latent HIV-1 by modulating the proviral transcription with the help of a specialized Cas9 mutant. Overcoming the limitations of the current therapy, CRISPR has the potential to become the primary genome editing tool for eradicating HIV-1 infection. In this review, we summarize the recent advancements of CRISPR to target the proviral HIV-1 genome, the challenges and future prospects.

12 January 2017 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
KGKrishna kumar Ganta
Krishna kumar Ganta
AMAnirban Mandal
Anirban Mandal
SDSukalyani Debnath
Sukalyani Debnath
BHBanasri Hazra
Banasri Hazra
BCBINAY CHAUBEY
BINAY CHAUBEY

1 September 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GPGabriela Pastuch-Gawolek
Gabriela Pastuch-Gawolek
BCBINAY CHAUBEY
BINAY CHAUBEY
Boguslaw SzewczykBoguslaw Szewczyk
Boguslaw Szewczyk
EKEwelina Krol
Ewelina Krol

18 November 2019 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
KGKrishna kumar Ganta
Krishna kumar Ganta
BCBINAY CHAUBEY
BINAY CHAUBEY
Introduction: With the introduction of highly active anti-retroviral therapy (HAART), treatment of HIV infection has improved radically, shifting the concept of HIV disease from a highly mortal epidemic to a chronic illness which needs systematic management. However, HAART does not target the integrated proviral DNA. Hence, prolonged use of antiviral drugs is needed for sustaining life. As a consequence, severe side effects emerge. Several parameters involve in causing these adverse effects. Mitochondrial dysfunctions were pointed as common factor among them. It is, therefore, necessary to critically examine mitochondrial dysfunction in order to understand the side effects. Areas covered: There are many events involved in causing drug-induced side-effects; in this review, we only highlight mitochondrial dysfunctions as one of the events. We present up-to-date findings on mitochondrial dysfunction caused by HIV infection and antiviral drug treatment. Both in vivo and in vitro studies on mitochondrial dysfunction like change in morphology, membrane depolarization, mitophagy, mitochondrial DNA depletion, and intrinsic apoptosis have been discussed. Expert opinion: Mitochondrial dysfunction is associated with severe complications that often lead to discontinuation or change in treatment regimen. Prior knowledge of side effects of antiviral drugs would help in better management and future research should focus to avoid mitochondrial targeting of antiviral drugs while maintaining their antiviral properties.